Northwestern Medicine names breast cancer OncoSET program

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NORTHWESTERN MEDICINE and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University officially named the Lynn Sage Cancer Research Foundation Breast Cancer OncoSET program.

LSCRF Breast Cancer OncoSET will combine oncology with genomic tumor profiling. The program will initially focus on patients with breast cancer that is non-responsive to traditional therapeutic treatments, and will serve as an extension of the Northwestern OncoSET program that was first launched earlier this year by the Lurie Cancer Center, in collaboration with Northwestern Memorial Hospital.

The Breast Cancer OncoSET program was made possible by a generous donation from the Lynn Sage Cancer Research Foundation, which is the first major naming gift that a Northwestern OncoSET program has received.

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login